Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-Term Safety Follow-Up

Protocol No
ARCELLX-ACLX-001-DDBCMA
Phase
I
Summary

This project is being done to study the effects of treatment with SPRX001 protein and ARC-T cells for the treatment of relapsed/refractory multiple myeloma.

Description
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Multiple Myeloma, Hematologic/Blood Related Cancers, Other Blood Related
ClinicalTrials.gov
go to website